Добірка наукової літератури з теми "Placental proteins"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Placental proteins".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Placental proteins"
Zhang, Yi, Yunhui Tang, Xinyi Sun, Matt Kang, Min Zhao, Jiayi Wan, and Qi Chen. "Exporting Proteins Associated with Senescence Repair via Extracellular Vesicles May Be Associated with Early Pregnancy Loss." Cells 11, no. 18 (September 6, 2022): 2772. http://dx.doi.org/10.3390/cells11182772.
Повний текст джерелаTang, Yunhui, Katie Groom, Larry Chamley, and Qi Chen. "Melatonin, a Potential Therapeutic Agent for Preeclampsia, Reduces the Extrusion of Toxic Extracellular Vesicles from Preeclamptic Placentae." Cells 10, no. 8 (July 27, 2021): 1904. http://dx.doi.org/10.3390/cells10081904.
Повний текст джерелаMayeur, Sylvain, Steve Lancel, Nicolas Theys, Marie-Amélie Lukaszewski, Sophie Duban-Deweer, Bruno Bastide, Johan Hachani, et al. "Maternal calorie restriction modulates placental mitochondrial biogenesis and bioenergetic efficiency: putative involvement in fetoplacental growth defects in rats." American Journal of Physiology-Endocrinology and Metabolism 304, no. 1 (January 1, 2013): E14—E22. http://dx.doi.org/10.1152/ajpendo.00332.2012.
Повний текст джерелаSzenasi, Nikolett Lilla, Eszter Toth, Andrea Balogh, Kata Juhasz, Katalin Karaszi, Oliver Ozohanics, Zsolt Gelencser, et al. "Proteomic identification of membrane-associated placental protein 4 (MP4) as perlecan and characterization of its placental expression in normal and pathologic pregnancies." PeerJ 7 (June 20, 2019): e6982. http://dx.doi.org/10.7717/peerj.6982.
Повний текст джерелаBarreto, Rodrigo da Silva Nunes, Ana Claudia Oliveira Carreira, Mônica Duarte da Silva, Leticia Alves Fernandes, Rafaela Rodrigues Ribeiro, Gustavo Henrique Doná Rodrigues Almeida, Bruna Tassia dos Santos Pantoja, Milton Yutaka Nishiyama Junior, and Maria Angelica Miglino. "Mice Placental ECM Components May Provide A Three-Dimensional Placental Microenvironment." Bioengineering 10, no. 1 (December 22, 2022): 16. http://dx.doi.org/10.3390/bioengineering10010016.
Повний текст джерелаGrimaldi, Brooke, Hamid-Reza Kohan-Ghadr та Sascha Drewlo. "The Potential for Placental Activation of PPARγ to Improve the Angiogenic Profile in Preeclampsia". Cells 11, № 21 (6 листопада 2022): 3514. http://dx.doi.org/10.3390/cells11213514.
Повний текст джерелаKumar K. V., Anil, Kavitha S., and Sreekanth K. S. "Regulatory proteins in placental angiogenesis." Biomedicine 41, no. 4 (December 31, 2021): 694–700. http://dx.doi.org/10.51248/.v41i4.944.
Повний текст джерелаAvissar, N., C. Eisenmann, J. G. Breen, S. Horowitz, R. K. Miller, and H. J. Cohen. "Human placenta makes extracellular glutathione peroxidase and secretes it into maternal circulation." American Journal of Physiology-Endocrinology and Metabolism 267, no. 1 (July 1, 1994): E68—E76. http://dx.doi.org/10.1152/ajpendo.1994.267.1.e68.
Повний текст джерелаTissot van Patot, M. C., J. Bendrick-Peart, V. E. Beckey, N. Serkova, and L. Zwerdlinger. "Greater vascularity, lowered HIF-1/DNA binding, and elevated GSH as markers of adaptation to in vivo chronic hypoxia." American Journal of Physiology-Lung Cellular and Molecular Physiology 287, no. 3 (September 2004): L525—L532. http://dx.doi.org/10.1152/ajplung.00203.2003.
Повний текст джерелаKarteris, E., D. Grammatopoulos, H. Randeva, and E. W. Hillhouse. "Signal Transduction Characteristics of the Corticotropin-Releasing Hormone Receptors in the Feto-Placental Unit." Journal of Clinical Endocrinology & Metabolism 85, no. 5 (May 1, 2000): 1989–96. http://dx.doi.org/10.1210/jcem.85.5.6590.
Повний текст джерелаДисертації з теми "Placental proteins"
Bojja, Aruna Sri. "Functional characterization of placental cathepsins." Access to citation, abstract and download form provided by ProQuest Information and Learning Company; downloadable PDF file, 81 p, 2009. http://proquest.umi.com/pqdweb?did=1885754561&sid=4&Fmt=2&clientId=8331&RQT=309&VName=PQD.
Повний текст джерелаEdwards, H. C. "Ca'2'+-sensitive proteins of the human placental microvillar cytoskeleton." Thesis, University of Leeds, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.304146.
Повний текст джерелаSealey, Amy Lynn. "Loss of the murine TATA-binding protein N terminus leads to placental labyrinth defects but not maternal adaptive immune responses." Thesis, Montana State University, 2007. http://etd.lib.montana.edu/etd/2007/sealey/SealeyA0507.pdf.
Повний текст джерелаSterle, Jodi A. "Effect of recombinant porcine somatotropin (rpST) on placental and fetal growth in gilts /." free to MU campus, to others for purchase, 1998. http://wwwlib.umi.com/cr/mo/fullcit?p9901288.
Повний текст джерелаHassanein, Mohamed. "Biochemical and functional characterization of a novel placental protease, cathepsin P, in rat trophoblasts." Access to citation, abstract and download form provided by ProQuest Information and Learning Company; downloadable PDF file, 148 p, 2007. http://proquest.umi.com/pqdweb?did=1654487491&sid=6&Fmt=2&clientId=8331&RQT=309&VName=PQD.
Повний текст джерелаBasir, Ghazala Sikandar. "Fetoplacental circulation and the role of IGF-1 in placental remodelling by apoptosis and proliferation in diabetic pregnancies." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B30496457.
Повний текст джерелаAna, Jakovljević. "Prognostički značaj laboratorijskih pokazatelja uteroplacentalne cirkulacije kod trudnica sa hipertenzijom i preeklampsijom." Phd thesis, Univerzitet u Novom Sadu, Medicinski fakultet u Novom Sadu, 2016. http://www.cris.uns.ac.rs/record.jsf?recordId=101331&source=NDLTD&language=en.
Повний текст джерелаINTRODUCTION: Hypertensive disorders in pregnancy are a heterogeneous group of diseases that occur in 3-8% of all pregnancies. The most difficult forms of these diseases: preeclampsia, eclampsia and HELLP syndrome are the leading causes of maternal and fetal morbidity and mortality in relation to all other pregnancy complications. Etiopathogenesis of these diseases is still insufficiently understood but it is thought that the placenta plays a key role in the development of these complications, and that placental insufficiency, which occurs as a result of insufficient adaptation of decidual intramiometrial and parts of the spiral arteries in the first few weeks of pregnancy, leading to a reduction of utero- placental circulation and local placental hypoxia, which adversely affects the mother and the fetus. In order to elucidate the pathophysiological mechanisms of hypertensive disorders in pregnancy and to find sufficiently sensitive makers for early prediction of the most severe forms of these diseases, so far have been investigated a number of proteins involved in the processes of creation and development of placental vascular network such as vascular endothelial growth factor (VEGF-A), placental growth factor (PlGF) and soluble fms-like receptor tyrosine kinase receptor (sFlt-1). OBJECTIVE: The aim of the study was to compare serum concentration of sFlt-1, PlGF, VEGF-A, PAPP-A, freeßhCG, glucose, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, apo-AI, apo B, AST, ALT, GGT, creatinine, urea, uric acid, hsCRP, Na, K, Cl, P, Mg and Ca between the group of pregnant women with preeclampsia, chronic and gestational hypertension and the control group of pregnant women in the first trimester of pregnancy between 11 and 14 weeks gestation. Also the aim was to examine whether the value of selected laboratory parameters (sFlt-1, VEGF-A and PlGF) differ in relation to gestational week at the time of birth, weight, length and APGAR scoring system of newborns. The aim was to examine whether the value of angiogenic proteins: sFlt-1, VEGF-A and PlGF differ significantly in relation to the number of previous pregnancies and age of the pregnant woman. MATERIALS AND METHODS: The study was conducted as a prospective analytical study in the Clinical Center of Vojvodina, in the period from June 2012 to February 2015. The study included a total of 143 pregnant women aged 18 - 43 years. All pregnant women included in the study were divided into two study and one control group. The first study group consisted of 43 pregnant women who developed preeclampsia during the current pregnancy. The second study group consisted of 46 pregnant women who are newly diagnosed or confirmed chronic or gestational hypertension during the current pregnancy. The control group consisted of 54 healthy pregnant women with verified physiological outcome of pregnancy at term without maternal and fetal complications. Patients were included in the study between 11 + 0 and 13 + 6 weeks of gestation. All patients had data about risk factors for developing hypertensive disorders in pregnancy. After clinical and obstetric examination all patients underwent anthropometric measurements, measurement of blood pressure, and specialized ultrasound examination to determine precise gestational age of the fetus and to determine the risk for fetal chromosomal abnormalities. All patients signed a written consent of the patient's voluntary participation in the study. Serum levels of sFlt1, VEGF-A and PlGF were determined by quantitative ELISA (R & D Systems Europe Ltd., Abingdon, UK), while glucose, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, apo-AI, apo B, AST, ALT, GGT, creatinine, urea, uric acid, hsCRP, Na, K, Cl, P, Mg, Ca were determined on automated analyzer systems. All pregnant women were categorized into 2 study and a control group on the basis of presence of hypertensive disorders in the current pregnancy. Statistical analysis was performed in 12 statistical program STATISTICA (StatSoft Inc., Tulsa, OK, USA). The data are presented in tables and graphs, the level of significance p is interpreted statistically significant if the p value was less than <0.05. RESULTS: Serum concentrations of sFlt-1 are statistically significantly different in all study groups and significantly higher in the groups with hypertensive disorders compared to healthy subjects p <0.001. Serum levels of VEGF-A are significantly lower in the preeclampsia group compared to healthy control group (p <0.001), while the levels of serum concentration of PlGF statistically significantly different between all groups so that the lowest values are observed in the preeclampsia group (p <0.001) compared to the other two study groups. There is no statistically significant differences in the levels of PAPP-A, biochemical parameters (glucose, AST, ALT, GGT creatinine, urea, uric acid), lipid parameters (total cholesterol, LDL, apo AI, apo B), inflammatory parameters (complete blood count, fibrinogen), hemostatic (D-dimer, vWF-antigen) and electrolyte status (Na, K, Cl, P, Mg, Ca), p> 0.05. Levels of free ßhCG and HDL cholesterol levels are significantly lower, while the value of hsCRP and triglycerides significantly higher in the group of women with preeclampsia compared to the healthy control group. Serum concentrations of sFlt-1 over 865 pg/ml have a sensitivity of 93% and specificity of 81.5% in predicting preeclampsia, while serum PlGF concentration below 60 pg/ml, a sensitivity of 88.4% and a specificity of 79.6% in predicting preeclampsia. Serum concentrations of sFlt-1, VEGF-A and PlGF do not show a statistically significant difference compared to the age of pregnant women and the number of previous pregnancies p> 0.05. Serum concentrations of sFlt-1 and PlGF are significantly different in relation to the weight of the newborn, so that the lower values of both proteins are in the group of infants with birth weight below 1500 gr. in relation to the body weight between 2800-3300 gr., p <0.001. There is also lower concentrations of sFlt-1 and PlGF in a group with deliveries before 33 weeks of gestation compared to the deliveries after 37 week of gestation, p <0.001. Serum concentrations of sFlt-1 and PlGF are significantly different in relation to the mother's body mass index so that the lower values of sFlt-1 and PlGF are in the group of women with a body mass index below 25 in relation to a group with a body mass index over 30 kg/m2, p <0.001. Serum concentrations of sFlt-1 in the first trimester of pregnancy were significantly associated with the parameters of inflammation (hsCRP), diastolic blood pressure and levels of free ßhCG. It is also observed a significant correlation between PlGF with a body mass index, systolic blood pressure and hsCRP concentration in the first trimester of pregnancy. CONCLUSION: The levels of anti-angiogenic protein sFlt-1 are higher in the group of pregnant women with preeclampsia than in the group with chronic and gestational hypertension and the control healthy group. Levels of proangiogenic VEGF-A protein are significantly lower in the preeclampsia group and group with gestational and chronic hypertension compared to the control group. Serum levels of proangiogenic PlGF protein are significantly lower in the preeclampsia group than in the group with chronic and gestational hypertension and the control group. Serum concentrations of placental protein free ßhCG and HDL cholesterol are significantly lower, while the value of hsCRP and triglycerides significantly higher in the preeclampsia group compared to the control group. Among pregnant women with hypertensive disorders in pregnancy and healthy pregnant women there are no significant differences in the values of placental PAPP-A protein, biochemical parameters (glucose, AST, ALT, GGT creatinine, urea, uric acid), lipid parameters (total cholesterol, LDL, apo AI, apo B), inflammatory parameters (complete blood count, fibrinogen), hemostatic (D-dimer, vWF-antigen) and electrolyte status (Na, K, Cl, P, Mg, Ca). Serum concentrations of sFlt-1 and PlGF are significantly different in relation to gestational age at delivery and newborn body weight and are lower in group with preterm delivery and newborns with lower birth weight. Serum concentrations of sFlt-1 are significantly different compared to body length and Apgar score, so that the higher values of sFlt-1 are associated with better outcome of newborns (greater body length and better APGAR score). Serum concentrations of sFlt-1, VEGF-A and PlGF are not different significantly with respect to age of pregnancy and the number of previous pregnancies. The levels of sFlt-1 and PlGF represents helpful markers in prediction of preeclampsia in the first trimester of pregnancy.
Rankin, Jonathan. "Exploring the Effect of Maternal Physical Activity and Placental Region on Mitochondrial Protein Content and Function in the Placenta." Thesis, Université d'Ottawa / University of Ottawa, 2019. http://hdl.handle.net/10393/39339.
Повний текст джерелаCosta, Rafaela Alkmin da. "Dosagem seriada dos fatores reguladores de angiogênese soluble fms-like tyrosine kinase-1 (sFlt-1) e placental growth factor (PIGF) para predição de pré-eclâmpsia e pré-eclâmpsia superajuntada." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/5/5139/tde-12012015-144329/.
Повний текст джерелаDespite being a major public health problem, the pathophysiology of preeclampsia is incompletely understood. Preeclampsia progression comprises a pre-clinical stage and a clinical stage. During the last decade much work has focused on identifying the pre-clinical stage of preeclampsia. Many researchers have clearly demonstrated an anti-angiogenic imbalance that is marked by higher levels of soluble fms-like tyrosine kinase-1 (sFlt-1) and lower levels of placental growth factor (PlGF) in the subjects who develop preeclampsia compared with those who do not. Although a growing number of studies in the high-risk population have shown the role of these biomarkers in diagnosing preeclampsia, superimposed preeclampsia, which can be a challenging diagnosis, remains partially understudied and the literature regarding this subject continues to be relatively scarce as well as controversial. By this study, we aimed to evaluate the performance of serial measurements of maternal circulating sFlt-1 and PlGF levels for the prediction of superimposed preeclampsia in chronic hypertensive subjects and to compare it to the prediction of preeclampsia in normotensive control subjects. For this purpose, we evaluated a two-armed prospective cohort of women with normotensive and chronic hypertensive pregnancies and assessed the serum levels of sFlt-1 and PlGF and the sFlt-1/PlGF ratio at gestational ages of 20, 26, 32 and 36 weeks, having preeclampsia as the primary outcome to be predicted. A total of 97 women were followed-up, 37 in the normotensive group and 60 in the chronic hypertensive group. Among them, 4 (10.8%) women developed preeclampsia and 14 (23.3%) developed superimposed preeclampsia. For predicting preeclampsia, PlGF at 20 gestational weeks presented an AUC=0.83 (CI 95% = 0.68 - 0.99, P=0.035) and the sFlt-1/PlGF ratio at 26 gestational weeks presented an AUC=0.92 (CI95% = 0.81 - 1.00, P=0.007). The percent change of the PlGF levels between 26 and 32 gestational weeks presented an AUC=0.96 (CI 95% = 0.89 - 1.00, P=0.003). For predicting superimposed preeclampsia, the sFlt-1/PlGF ratio at 32 gestational weeks presented an AUC=0.69 (CI 95% = 0.53 - 0.85, P=0.039). Between 20 and 26 gestational weeks, the percent change of PlGF and the sFlt-1/PlGF ratio presented, respectively, an AUC=0.74 (CI 95% = 0.58 - 0.90, P=0.018) and an AUC=0.71 (CI 95% = 0.52 - 0.91, P=0.034). By our results, we concluded that, although the PlGF level and the sFlt-1/PlGF ratio present good performances in the prediction of preeclampsia, caution is required when using them for the prediction of superimposed preeclampsia. Sequential assessments slightly improve the test performances for predicting superimposed preeclampsia at earlier gestational ages
Rao, M. Rekha. "Functional Differentiation Of The Human Placenta : Insights From The Expression Of Two Developmentally - Regulated Genes." Thesis, Indian Institute of Science, 2000. http://hdl.handle.net/2005/177.
Повний текст джерелаКниги з теми "Placental proteins"
Matsuto, Mochizuki, and Hussa Robert O, eds. Placental protein hormones: Proceedings of the Satellite Symposium on Placental Protein Hormones, Kobe, Japan, 14-15 July 1988. Amsterdam: Excerpta Medica, 1988.
Знайти повний текст джерелаInternational Congress on Placental and Endometrial Proteins (6th 1987 Nagoya-shi, Japan). Placental and endometrial proteins: Basic and clinical aspects : proceedings of the 6th International Congress on Placental and Endometrial Proteins, Nagoya, Japan, 13 December 1987. Utrecht, the Netherlands: VSP, 1988.
Знайти повний текст джерелаInternational Conference on Placenta (1990 Tokyo, Japan). Placenta: Basic research for clinical application. Edited by Soma H. Basel: Karger, 1991.
Знайти повний текст джерелаP, Bischof, and Klopper Arnold, eds. Proteins of the placenta: Biochemistry, biology, and clinical application. Basel ; New York: Karger, 1985.
Знайти повний текст джерелаPlacental Proteins. Springer, 2012.
Знайти повний текст джерелаKlopper, A., and T. Chard. Placental Proteins. Springer London, Limited, 2012.
Знайти повний текст джерела(Editor), Matsuto Mochizuki, and Robert Hussa (Editor), eds. Placental Protein Hormones (International Congress). Elsevier, 1988.
Знайти повний текст джерелаLise, Cédard, and Firth Anthony, eds. Placental signals: Autocrine and paracine control of pregnancy. Rochester, N.Y: University of Rochester Press, 1992.
Знайти повний текст джерелаPlacental Signals Autocrine and Paracine Control of Pregnancy (Trophoblast Research). University of Rochester Press, 1993.
Знайти повний текст джерелаMizutani, S. Placental And Endometrial Proteins: Basic And Clinical Aspects: Proceedings of the International Conference, Japan, 1987. Brill Academic Publishers, 1988.
Знайти повний текст джерелаЧастини книг з теми "Placental proteins"
Burch, Rebecca L. "Placental Proteins in Semen." In Encyclopedia of Evolutionary Psychological Science, 1–4. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-16999-6_2009-1.
Повний текст джерелаBurch, Rebecca L. "Placental Proteins in Semen." In Encyclopedia of Evolutionary Psychological Science, 6010–13. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-319-19650-3_2009.
Повний текст джерелаB. Hertz, J., and P. Schultz-Larsen. "PLACENTAL PROTEINS IN THREATENED ABORTION." In Pregnancy Proteins in Animals, edited by Jann Hau, 31–40. Berlin, Boston: De Gruyter, 1986. http://dx.doi.org/10.1515/9783110858167-006.
Повний текст джерелаE.Bolton, A., K. J.Clough, H. Bohn, and M. G. Chapman. "PLACENTAL PROTEIN 14 (PP14) IN THE HUMAN REPRODUCTIVE TRACT." In Pregnancy Proteins in Animals, edited by Jann Hau, 165–72. Berlin, Boston: De Gruyter, 1986. http://dx.doi.org/10.1515/9783110858167-017.
Повний текст джерелаRutanen, E.-M., M. Menabawey, T. Chard, J. G. Grudzinskas, M. Seppälä, and H. Bohn. "THE MAJOR SOURCE OF PLACENTAL PROTEIN 12 IS DECIDUA/ENDOMETRIUM." In Pregnancy Proteins in Animals, edited by Jann Hau, 123–30. Berlin, Boston: De Gruyter, 1986. http://dx.doi.org/10.1515/9783110858167-014.
Повний текст джерелаA. Forsyth, Isabel, and Glenys A. Bloomfield. "PLACENTAL LACTOGEN AND OTHER PREGNANCY-SPECIFIC PROTEINS IN FARM ANIMALS." In Pregnancy Proteins in Animals, edited by Jann Hau, 505–10. Berlin, Boston: De Gruyter, 1986. http://dx.doi.org/10.1515/9783110858167-048.
Повний текст джерелаG.Grudzinskas, J., J. G. Westergaard, and B. Teisner. "CLINICAL ASPECTS OF PLACENTAL PROTEIN MEASUREMENTS IN EARLY PREGNANCY AND ITS COMPLICATIONS." In Pregnancy Proteins in Animals, edited by Jann Hau, 21–28. Berlin, Boston: De Gruyter, 1986. http://dx.doi.org/10.1515/9783110858167-004.
Повний текст джерелаStigbrand, T., and K. Hirano. "THE SIGNIFICANCE OF PLACENTAL ALKALINE PHOSPHATASE AS A PREGNANCY RELATED PROTEIN IN MAN AND ANIMALS." In Pregnancy Proteins in Animals, edited by Jann Hau, 235–46. Berlin, Boston: De Gruyter, 1986. http://dx.doi.org/10.1515/9783110858167-026.
Повний текст джерелаSchneider, H., A. Malek, R. Duft, and N. Bersinger. "Evaluation of an In Vitro Dual Perfusion System for the Study of Placental Proteins: Energy Metabolism." In Placenta as a Model and a Source, 39–50. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4613-0823-2_4.
Повний текст джерелаBährle-Rapp, Marina. "Placental Protein." In Springer Lexikon Kosmetik und Körperpflege, 432. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-71095-0_8032.
Повний текст джерелаТези доповідей конференцій з теми "Placental proteins"
Ny, T., L. Hansson, and B. Åstedt. "ISOLATION OF cDNA FOR TYPE-2 PLASMINOGEN ACTIVATOR INHIBITOR." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642855.
Повний текст джерелаBukowski, Michael, Brij Singh, James Roemmich, and Kate Larson. "Lipidomic analysis of TRPC1 Ca2+-permeable channel-knock out mouse demonstrates a vital role in placental tissue sphingolipid and triacylglycerol homeostasis under high-fat diet." In 2022 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2022. http://dx.doi.org/10.21748/tjdt4839.
Повний текст джерелаFujikawa, K., T. Funakoshi, J. F. Tait, and R. L. Heimark. "PLACENTAL ANTICOAGULANT PROTEIN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643912.
Повний текст джерелаFujikawa, K., T. Funakoshi, R. L. Heimark, and J. F. Tait. "HUMAN PLACENTAL ANTICOAGULANT PROTEIN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642949.
Повний текст джерелаContant, g., E. Anglescano, and J. L. Martinoli. "A SIMPLE AND RAPID PLASMINOGEN ACTIVATOR INHIBITOR (PAI) ASSAY IN PLASMA, USING A UNIQUE CONCENTRATION OF TISSUE PLASMINOGEN ACTIVATOR (tPA) AND PAI-DEPLETED PLASMA." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644452.
Повний текст джерелаMatsumoto, T., K. Kanamaru, Y. Sugiyama, and K. Deguchi. "HEMATOLOGICAL CHARACTERISTICS OF PREGNANT BLOOD AND LOCALIZATION OF THROMBOMODULIN IN HUMAN PLACENTAL VILLOUS TISSUE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644299.
Повний текст джерелаMenezes, A. C. B., T. L. Neville, M. S. Crouse, K. J. McLean, A. K. Ward, L. P. Reynolds, C. R. Dahlen, et al. "Nutrition and early pregnancy in beef heifers: impacts on CAT2 abundance in utero-placental tissues." In 6th EAAP International Symposium on Energy and Protein Metabolism and Nutrition. The Netherlands: Wageningen Academic Publishers, 2019. http://dx.doi.org/10.3920/978-90-8686-891-9_52.
Повний текст джерелаBagley, Rebecca G., Leslie Kurtzberg, William Weber, Tri‐Hung Nguyen, Gwen Lovewell, Cokey Nguyen, Min Yao, et al. "Abstract A14: sFLT01: An antiangiogenic protein that neutralizes placental growth factor." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-a14.
Повний текст джерелаTanaka, H., N. Narahara, H. Sadakata, K. Andoh, N. Kobayashi, and T. Maekawa. "ANALYSIS OF LEUKEMIA PELT. TISSUE FACTOR BY WESTERN BLOTTING TECHNIQUE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643285.
Повний текст джерелаWiesel, M. L., R. Spaethe, J.-M. Freyssinet, T. Tran, H.-J. Kolde, J. P. Cazenave, L. Grunebaum, and Z. Vavra. "DETECTION AND EFFECTS OF THROMBOMODULIN ACTIVITY IN CRUDE THROMBOPLASTIN PREPARATIONS FROM PLACENTA AND LUNG." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644300.
Повний текст джерелаЗвіти організацій з теми "Placental proteins"
Bremel, Robert D., and Arieh Gertler. Effect of Bovine Placental Lactogen and other Placental Proteins on Growth and Differentiation of Cultured Bovine Mammary Cells. United States Department of Agriculture, September 1986. http://dx.doi.org/10.32747/1986.7566755.bard.
Повний текст джерелаBazer, Fuller W., Arieh Gertler, and Elisha Gootwine. Role of Placental Lactogen in Sheep. United States Department of Agriculture, January 2001. http://dx.doi.org/10.32747/2001.7574339.bard.
Повний текст джерелаSplitter, Gary, and Menachem Banai. Microarray Analysis of Brucella melitensis Pathogenesis. United States Department of Agriculture, 2006. http://dx.doi.org/10.32747/2006.7709884.bard.
Повний текст джерелаSplitter, Gary A., Menachem Banai, and Jerome S. Harms. Brucella second messenger coordinates stages of infection. United States Department of Agriculture, January 2011. http://dx.doi.org/10.32747/2011.7699864.bard.
Повний текст джерелаBaszler, Timothy, Igor Savitsky, Christopher Davies, Lauren Staska, and Varda Shkap. Identification of bovine Neospora caninum cytotoxic T-lymphocyte epitopes for development of peptide-based vaccine. United States Department of Agriculture, March 2006. http://dx.doi.org/10.32747/2006.7695592.bard.
Повний текст джерела